Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression

Abstract Introduction Current therapies for multiple sclerosis (MS) primarily reduce relapse rates and delay disability by targeting inflammation, while have limited efficacy against disease progression driven by neurodegenerative processes. We sought to identify and validate proteins for MS progres...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuan Jiang, Jinyu Xiao, Ingrid Kockum, Pernilla Stridh, Qianwen Liu, Tomas Olsson, Lars Alfredsson, Xia Jiang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-06-01
coleção:	Journal of Neuroinflammation
Assuntos:	Progressive multiple sclerosis Protein Drug targets Omics
Acesso em linha:	https://doi.org/10.1186/s12974-026-03895-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!